Wang et al. (2021) reported that ABCG2 rs1871744 and rs4148157 genotype were significantly associated with the poor response in cancer patients receiving platinum-based chemotherapy. Palshof et al. (2020) found that colorectal cancer patients with low ABCG2 expression level had a higher chance of obtaining objective response when receiving irinotecan-based treatment. This evidence concerns the gene ABCG2 and colorectal cancer.